- |||||||||| levofloxacin / Generic mfg.
[VIRTUAL] MISTAKES IN DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF HELICOBACTER PYLORI INFECTION IN THE LAST DECADE (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_4210; However, despite the use of quadruple therapies and optimized treatments (longer duration and using esomeprazol), the efficacy in daily clinical practice is far from the aimed 90%. Although the management of the infection should be individualized in daily clinical practice, we showed an overuse of endoscopy in dyspeptic patients under the age of 55 years, an non-adequate drug prescription in 23.6% of the cases, a use of regimens not included in clinical guidelines (like levofloxacin-based triple therapy as first-line), and the establishment of treatment for patients with non-indicated pathologies.
- |||||||||| clarithromycin / Generic mfg., amoxicillin / Generic mfg.
[VIRTUAL] FIRST LINE ERADICATION THERAPY FOR HELICOBACTER PYLORI GUIDED BY MOLECULAR ANALYSIS OF GENOTYPIC RESISTANCES ON STOOLS: A PILOT STUDY (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_4207; Resistance to amoxicillin, clarithromycin, metronidazole, levofloxacin and tetracycline were analyzed by real time polymerase chain reaction (PCR) analysis of PBP-1A, 23s rRNA, RdxA/FrxA, gyrA and 16S rRNA genes, respectively.In the case of absence of resistance, concomitant therapy was assigned; in the case of clarithromycin resistance, 3-in-1 pill bismuth quadruple therapy was given...If triple resistance clarithromycin-tetracycline-levofloxacin was detected, triple therapy with rifabutin was suggested... In first line, a tailored therapy shows a satisfactory success rate, above the 90% with the relevant advantage to reduce failure rate to less than 10%.
- |||||||||| levofloxacin / Generic mfg.
[VIRTUAL] MISTAKES IN DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF HELICOBACTER PYLORI INFECTION IN THE LAST DECADE (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_2030; However, despite the use of quadruple therapies and optimized treatments (longer duration and using esomeprazol), the efficacy in daily clinical practice is far from the aimed 90%. Although the management of the infection should be individualized in daily clinical practice, we showed an overuse of endoscopy in dyspeptic patients under the age of 55 years, an non-adequate drug prescription in 23.6% of the cases, a use of regimens not included in clinical guidelines (like levofloxacin-based triple therapy as first-line), and the establishment of treatment for patients with non-indicated pathologies.
- |||||||||| clarithromycin / Generic mfg., amoxicillin / Generic mfg.
[VIRTUAL] FIRST LINE ERADICATION THERAPY FOR HELICOBACTER PYLORI GUIDED BY MOLECULAR ANALYSIS OF GENOTYPIC RESISTANCES ON STOOLS: A PILOT STUDY (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_2027; Resistance to amoxicillin, clarithromycin, metronidazole, levofloxacin and tetracycline were analyzed by real time polymerase chain reaction (PCR) analysis of PBP-1A, 23s rRNA, RdxA/FrxA, gyrA and 16S rRNA genes, respectively.In the case of absence of resistance, concomitant therapy was assigned; in the case of clarithromycin resistance, 3-in-1 pill bismuth quadruple therapy was given...If triple resistance clarithromycin-tetracycline-levofloxacin was detected, triple therapy with rifabutin was suggested... In first line, a tailored therapy shows a satisfactory success rate, above the 90% with the relevant advantage to reduce failure rate to less than 10%.
- |||||||||| levofloxacin / Generic mfg.
[VIRTUAL] MISTAKES IN DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF HELICOBACTER PYLORI INFECTION IN THE LAST DECADE (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_199; However, despite the use of quadruple therapies and optimized treatments (longer duration and using esomeprazol), the efficacy in daily clinical practice is far from the aimed 90%. Although the management of the infection should be individualized in daily clinical practice, we showed an overuse of endoscopy in dyspeptic patients under the age of 55 years, an non-adequate drug prescription in 23.6% of the cases, a use of regimens not included in clinical guidelines (like levofloxacin-based triple therapy as first-line), and the establishment of treatment for patients with non-indicated pathologies.
- |||||||||| clarithromycin / Generic mfg., amoxicillin / Generic mfg.
[VIRTUAL] FIRST LINE ERADICATION THERAPY FOR HELICOBACTER PYLORI GUIDED BY MOLECULAR ANALYSIS OF GENOTYPIC RESISTANCES ON STOOLS: A PILOT STUDY (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_196; Resistance to amoxicillin, clarithromycin, metronidazole, levofloxacin and tetracycline were analyzed by real time polymerase chain reaction (PCR) analysis of PBP-1A, 23s rRNA, RdxA/FrxA, gyrA and 16S rRNA genes, respectively.In the case of absence of resistance, concomitant therapy was assigned; in the case of clarithromycin resistance, 3-in-1 pill bismuth quadruple therapy was given...If triple resistance clarithromycin-tetracycline-levofloxacin was detected, triple therapy with rifabutin was suggested... In first line, a tailored therapy shows a satisfactory success rate, above the 90% with the relevant advantage to reduce failure rate to less than 10%.
- |||||||||| clarithromycin / Generic mfg., amoxicillin / Generic mfg.
Clinical, Journal: Novel "High-dose Quad" Salvage Therapy Approach for Helicobacter pylori Infection: A Case Report. (Pubmed Central) - Jul 17, 2021 This case describes an 84-year-old American woman with chronic H. pylori gastritis who failed two first-line treatment regimens (bismuth quadruple therapy and concomitant therapy), but responded to a novel, "high-dose quad" salvage regimen consisting of high-dose levofloxacin, amoxicillin, metronidazole, and high-dose acid suppression. This is the first time the "high-dose quad" regimen has been reviewed in the literature and is not FDA approved, but may be considered as an alternative salvage therapy in certain patients, based on the efficacy and safety observed in this case.
- |||||||||| ampicillin / Generic mfg.
Journal: Ampicillin triggers the release of Pal in toxic vesicles from Escherichia coli. (Pubmed Central) - Jul 17, 2021 The OMVs were purified by ultracentrifugation and characterized by transmission electron microscopy and nanoparticle tracking analysis, and Pal and other E. coli proteins were detected by western blot. We also propose that sepsis treatments using certain beta-lactam antibiotics may further aggravate the over-exuberant inflammatory response by enhancing the release of Pal and LPS in OMVs.
- |||||||||| clarithromycin / Generic mfg.
Journal: Early genetic diagnosis of clarithromycin resistance in Helicobacter pylori. (Pubmed Central) - Jul 17, 2021 To effectively control antimicrobial resistance among pathogens, we advocate extensive and dynamic monitoring of MDR bacteria, coupled with careful use of antibiotics. Hp1181 and hp1184 mutations may be the earliest and most persistent response to clarithromycin resistance, and they may be the potential target genes for the diagnosis, prevention, and treatment of clarithromycin resistance.
- |||||||||| ciprofloxacin oral / Generic mfg., levofloxacin / Generic mfg., moxifloxacin intravenous / Generic mfg.
Journal, Adverse events: Systemic quinolones and risk of acute liver failure I: Analysis of data from the US FDA adverse event reporting system. (Pubmed Central) - Jul 16, 2021 Only ciprofloxacin showed a marginal and significant AHF signal (PRR: 1.85 [1.21, 2.81]; EBGM: 1.54 [1.06, 1.81]); moxifloxacin, levofloxacin, and ofloxacin showed weak and nonsignificant signals. Further pharmacovigilance studies are required to confirm the association between ciprofloxacin and AHF seen in the present analysis.
- |||||||||| Journal: Spread of multidrug resistance among Ureaplasma serovars, Tunisia. (Pubmed Central) - Jul 15, 2021
Ofloxacin and levofloxacin resistance was found in 73.27 and 17.82%, respectively, while 37.62% of isolates proved resistant to tetracycline...In most cases, drug resistance was found to be associated with known molecular mechanisms, yet we have identified two novel mutations in the L22 protein, which might be associated with macrolide-resistance. To our knowledge, this is the first study that reports the widespread expansion of multidrug resistance among Ureaplasma serovars, a finding of importance in terms of both surveillance and antimicrobial usage.
- |||||||||| levofloxacin / Generic mfg.
Clinical, Journal: Gitelman-like syndrome: A rare complication of using aminoglycosides in tuberculosis - A case report. (Pubmed Central) - Jul 15, 2021 Approximately 8-26% of patients who receive an aminoglycoside for several days develop mild renal impairment that is almost always reversible (Brunton et al., 2013). A 46 year old male with multi-drug-resistant pulmonary tuberculosis with resistance to kanamycin is being presented, who was on injectable Capreomycin, Levofloxacin, Ethionamide, Cycloserine, pyrazinamide, linezolid and clofazamine for a period of four months...This features mimic Gitelman's syndrome which is an autosomal recessive disorder affecting kidneys causing electrolyte disturbances. The drug was immediately withdrawn and electrolyte correction was given and the condition reversed gradually.
- |||||||||| ampicillin / Generic mfg.
Journal: Correlation of minimum inhibitory concentrations between human and animal antimicrobials against Escherichia coli isolated from livestock. (Pubmed Central) - Jul 15, 2021 The percentage agreement for susceptibility, defined as the percentage of isolates sensitive to both antimicrobials compared with isolates sensitive to both antimicrobials, as well as those sensitive only to the human antimicrobial, was 89.9%, 87.3%, 64.0%, and 89.9% for PIPC and ABPC, AMK and KM, MINO and OTC, and LVFX and ERFX, respectively. Our results suggest that the possibility of missing the resistance for antimicrobials used in human medicine by examining MICs for the equivalent antimicrobials used in veterinary medicine is low.
- |||||||||| ciprofloxacin oral / Generic mfg., levofloxacin / Generic mfg.
Preclinical, Journal: Development of in vitro resistance to fluoroquinolones in Pseudomonas aeruginosa. (Pubmed Central) - Jul 14, 2021 These results demonstrated gyrA mutation and MexCD-OprJ overexpression as the primary mechanism conferring ciprofloxacin and levofloxacin resistance in P. aeruginosa. In addition, we also show that ciprofloxacin exhibited a stronger ability to kill the bacteria while potentially rendering it more susceptible to resistance.
- |||||||||| levofloxacin / Generic mfg.
Journal: The optimization of enzymatic oxidation of levofloxacin, a fluoroquinolone antibiotic for wastetwater treatment. (Pubmed Central) - Jul 14, 2021 The biodegradation studies were conducted using only 2 units of laccase. Thus, the expensive commercial laccase can be effectively replaced by crude laccase isolated from indigenous macrofungi such as P. eryngii, P. florida and P. sajor caju as a cost effective alternative to degrade levofloxacin present in contaminated wastewater using as low as 2 units of enzyme for a 72 h treatment period.
|